Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Wyeth Premarin Market-Share Rebates Challenged In Duramed Antitrust Suit

Executive Summary

Wyeth-Ayerst's Premarin market share-based rebates represent an antitrust violation, Duramed maintained in a lawsuit filed Sept. 5 in Cincinnati federal court.

You may also be interested in...



Cenestin Settlement: Barr Boosts Branded Business With Five Wyeth Products

Barr will add an oral contraceptive in development at Wyeth as part of an acquisition deal that settles Cenestin antitrust litigation

Cenestin Settlement: Barr Boosts Branded Business With Five Wyeth Products

Barr will add an oral contraceptive in development at Wyeth as part of an acquisition deal that settles Cenestin antitrust litigation

Wyeth Wants Premarin Petitions Excluded From Duramed Antitrust Suit

Wyeth-Ayerst's efforts to influence regulatory decisions about conjugated estrogens via citizens' petitions are an early focus of arguments in Duramed's antitrust suit against the company.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS036618

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel